Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) said the 400 million yuan venture capital fund it invested in completed its industrial and commercial registration, according to a Shanghai Stock Exchange disclosure on Tuesday.

The fund, Guangzhou Guangyao Industrial Investment Venture Capital Fund Partnership (Limited Partnership), completed the filing procedures with the Asset Management Association of China, the pharmaceutical company said.

Baiyunshan Pharma's Shanghai shares slipped more than 1% and Hong Kong shares fell less than 2% in recent trade.